SK bioscience and Partners Secure $30 Million for Ebola Vaccine Development

SK bioscience, in collaboration with MSD and Hilleman Laboratories, has announced significant progress in the development of a vaccine for the Zaire ebolavirus, supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The funding agreement, revealed on January 22, 2026, allows CEPI to allocate up to USD 30 million to MSD for advancing the vaccine’s development. This funding will be directed to key partners, including SK bioscience and Hilleman Laboratories, which is a joint initiative between MSD and the global health research charity Wellcome.

This collaboration builds upon MSD’s existing Zaire ebolavirus vaccine, which has received prequalification from the World Health Organization (WHO). The focus of this partnership is to enhance the current manufacturing process, which is noted for its complexity and the need for ultra-low temperature storage. Such logistical challenges often hinder vaccine distribution in remote areas that are most affected by Ebola outbreaks.

Improving the manufacturing yield and enhancing the vaccine’s thermostability are critical goals of this initiative. By addressing these issues, the project aims to ensure a more affordable and sustainable supply of the vaccine, contingent on regulatory approvals and public health guidelines. Under this agreement, Hilleman Laboratories will spearhead the clinical development of the updated vaccine, while SK bioscience and IDT Biologika will refine the drug substance manufacturing process and the accompanying drug product.

Dr. Richard Hatchett, CEO of CEPI, emphasized the significance of this funding, stating, “In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks.” He added that this support from CEPI will enable a sustainable and accessible supply of MSD’s Zaire ebolavirus vaccine, ultimately contributing to saving lives.

Echoing this sentiment, Jaeyong Ahn, CEO of SK bioscience, remarked, “Addressing deadly infectious diseases such as Ebola requires strong global collaboration.” He highlighted the company’s commitment to enhancing the manufacturing and supply of the Zaire ebolavirus vaccine, thereby contributing to global health preparedness.

Zaire ebolavirus is responsible for unpredictable outbreaks, with a survival rate hovering around 50%. Recent incidents in the Democratic Republic of the Congo and other regions have underscored the persistent threat posed by the virus, particularly in areas with limited healthcare access and infrastructure.

SK bioscience has a proven track record of collaboration with various global health organizations, including CEPI, the Gates Foundation, and the International Vaccine Institute (IVI). By leveraging its comprehensive capabilities across development, manufacturing, and supply, the company continues to strengthen its role as a key partner in public health initiatives aimed at vaccine accessibility.

In summary, the collaboration between SK bioscience, MSD, and Hilleman Laboratories, backed by CEPI funding, represents a significant step toward improving the availability of a vital vaccine against a deadly virus. This effort not only aims to enhance public health responses but also reflects a broader commitment to global health equity and preparedness.